Completed PHASE1/PHASE2 INTERVENTIONAL NCT00062816

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

Sponsor: Ionis Pharmaceuticals, Inc.

Interventions ISIS 14803, peginterferon alfa, ribavirin

Updated 7 times since 2017 Last updated: Dec 1, 2022 Started: Jun 30, 2003 Primary completion: Jan 31, 2004 Completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00062816, this PHASE1/PHASE2 trial focuses on Hepatitis C, Chronic and remains completed. Sponsored by Ionis Pharmaceuticals, Inc., it has been updated 7 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Jan 2023 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ionis Pharmaceuticals, Inc.

Data source: Ionis Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altoona, United States , Bellevue, United States , Birmingham, United States , Boise, United States , Boston, United States , Cincinnati, United States , Colorado Springs, United States , Durham, United States , Germantown, United States , Houston, United States and 15 more locations